These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 7702626)

  • 1. Correction of fumarylacetoacetate hydrolase deficiency (type I tyrosinemia) in cultured human fibroblasts by retroviral-mediated gene transfer.
    Phaneuf D; Hadchouel M; Tanguay RM; Bréchot C; Ferry N
    Biochem Biophys Res Commun; 1995 Mar; 208(3):957-63. PubMed ID: 7702626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine and its catabolites: from disease to cancer.
    Tanguay RM; Jorquera R; Poudrier J; St-Louis M
    Acta Biochim Pol; 1996; 43(1):209-16. PubMed ID: 8790725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in the fumarylacetoacetate hydrolase gene causing hereditary tyrosinemia type I: overview.
    St-Louis M; Tanguay RM
    Hum Mutat; 1997; 9(4):291-9. PubMed ID: 9101289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deficient fumarylacetoacetate fumarylhydrolase activity in lymphocytes and fibroblasts from patients with hereditary tyrosinemia.
    Kvittingen EA; Halvorsen S; Jellum E
    Pediatr Res; 1983 Jul; 17(7):541-4. PubMed ID: 6622096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hereditary tyrosinemia type I--an overview.
    Kvittingen EA
    Scand J Clin Lab Invest Suppl; 1986; 184():27-34. PubMed ID: 3296130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Localization of cells in the rat brain expressing fumarylacetoacetate hydrolase, the deficient enzyme in hereditary tyrosinemia type 1.
    Labelle Y; Puymirat J; Tanguay RM
    Biochim Biophys Acta; 1993 Jan; 1180(3):250-6. PubMed ID: 8422430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I).
    Tanguay RM; Valet JP; Lescault A; Duband JL; Laberge C; Lettre F; Plante M
    Am J Hum Genet; 1990 Aug; 47(2):308-16. PubMed ID: 2378356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations of the fumarylacetoacetate hydrolase gene in four patients with tyrosinemia, type I.
    Grompe M; al-Dhalimy M
    Hum Mutat; 1993; 2(2):85-93. PubMed ID: 8318997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Self-induced correction of the genetic defect in tyrosinemia type I.
    Kvittingen EA; Rootwelt H; Berger R; Brandtzaeg P
    J Clin Invest; 1994 Oct; 94(4):1657-61. PubMed ID: 7929843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I.
    Overturf K; Al-Dhalimy M; Tanguay R; Brantly M; Ou CN; Finegold M; Grompe M
    Nat Genet; 1996 Mar; 12(3):266-73. PubMed ID: 8589717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different clinical forms of hereditary tyrosinemia (type I) in patients with identical genotypes.
    Poudrier J; Lettre F; Scriver CR; Larochelle J; Tanguay RM
    Mol Genet Metab; 1998 Jun; 64(2):119-25. PubMed ID: 9705236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type 1 hereditary tyrosinemia. Evidence for molecular heterogeneity and identification of a causal mutation in a French Canadian patient.
    Phaneuf D; Lambert M; Laframboise R; Mitchell G; Lettre F; Tanguay RM
    J Clin Invest; 1992 Oct; 90(4):1185-92. PubMed ID: 1401056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the human fumarylacetoacetate hydrolase gene and identification of a missense mutation abolishing enzymatic activity.
    Labelle Y; Phaneuf D; Leclerc B; Tanguay RM
    Hum Mol Genet; 1993 Jul; 2(7):941-6. PubMed ID: 8364576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect.
    Kvittingen EA; Rootwelt H; Brandtzaeg P; Bergan A; Berger R
    J Clin Invest; 1993 Apr; 91(4):1816-21. PubMed ID: 8473520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cloning and expression of the cDNA encoding human fumarylacetoacetate hydrolase, the enzyme deficient in hereditary tyrosinemia: assignment of the gene to chromosome 15.
    Phaneuf D; Labelle Y; Bérubé D; Arden K; Cavenee W; Gagné R; Tanguay RM
    Am J Hum Genet; 1991 Mar; 48(3):525-35. PubMed ID: 1998338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I.
    Grompe M; St-Louis M; Demers SI; al-Dhalimy M; Leclerc B; Tanguay RM
    N Engl J Med; 1994 Aug; 331(6):353-7. PubMed ID: 8028615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries.
    Bergman AJ; van den Berg IE; Brink W; Poll-The BT; Ploos van Amstel JK; Berger R
    Hum Mutat; 1998; 12(1):19-26. PubMed ID: 9633815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variable gene expression within human tyrosinemia type 1 liver may reflect region-specific dysplasia.
    Haber BA; Chuang E; Lee W; Taub R
    Hepatology; 1996 Jul; 24(1):65-71. PubMed ID: 8707285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purification of mRNA coding for the enzyme deficient in hereditary tyrosinemia, fumarylacetoacetate hydrolase.
    Nicole LM; Valet JP; Laberge C; Tanguay RM
    Biochem Cell Biol; 1986 May; 64(5):489-93. PubMed ID: 3718716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoplasmic nonsense-mediated mRNA decay for a nonsense (W262X) transcript of the gene responsible for hereditary tyrosinemia, fumarylacetoacetate hydrolase.
    Dreumont N; Maresca A; Khandjian EW; Baklouti F; Tanguay RM
    Biochem Biophys Res Commun; 2004 Nov; 324(1):186-92. PubMed ID: 15465000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.